Predictive Power of Tertiary Lymphoid Structure Signature for Neoadjuvant Chemotherapy Response and Immunotherapy Benefit in HER2-negative Breast Cancer

Overview

Journal Cancer Commun (Lond)

Publisher Wiley

Specialty Oncology

Date 2023 Jun 6

PMID 37278484

Authors

Francois Bertucci

Alexandre de Nonneville

Pascal Finetti

Emilie Mamessier

Affiliations

Soon will be listed here.

Citing Articles

B cells and tertiary lymphoid structures in tumors: immunity cycle, clinical impact, and therapeutic applications.

Wu X, Huang Q, Chen X, Zhang B, Liang J, Zhang B Theranostics. 2025; 15(2):605-631.

PMID: 39744696 PMC: 11671382. DOI: 10.7150/thno.105423.

Global trends in tertiary lymphoid structures: a bibliometric analysis from 2014 to 2023.

Bao Y, Mo Z, Wang S, Long J, Zhang H, Xu Y Front Immunol. 2024; 15:1475062.

PMID: 39620224 PMC: 11604643. DOI: 10.3389/fimmu.2024.1475062.

Tertiary lymphoid structures in cancer: immune mechanisms and clinical implications.

Wang S, Wang H, Li C, Liu B, He S, Tu C MedComm (2020). 2024; 5(3):e489.

PMID: 38469550 PMC: 10925885. DOI: 10.1002/mco2.489.

Tertiary lymphoid structures predict survival and response to neoadjuvant therapy in locally advanced rectal cancer.

Wang Q, Zhong W, Shen X, Hao Z, Wan M, Yang X NPJ Precis Oncol. 2024; 8(1):61.

PMID: 38431733 PMC: 10908779. DOI: 10.1038/s41698-024-00533-w.

Heterogeneity of tertiary lymphoid structures in cancer.

You X, Koop K, Weigert A Front Immunol. 2023; 14:1286850.

PMID: 38111571 PMC: 10725932. DOI: 10.3389/fimmu.2023.1286850.

References

Ayers M, Lunceford J, Nebozhyn M, Murphy E, Loboda A, Kaufman D . IFN-γ-related mRNA profile predicts clinical response to PD-1 blockade. J Clin Invest. 2017; 127(8):2930-2940. PMC: 5531419. DOI: 10.1172/JCI91190. View

Sautes-Fridman C, Petitprez F, Calderaro J, Fridman W . Tertiary lymphoid structures in the era of cancer immunotherapy. Nat Rev Cancer. 2019; 19(6):307-325. DOI: 10.1038/s41568-019-0144-6. View

Gu-Trantien C, Loi S, Garaud S, Equeter C, Libin M, De Wind A . CD4⁺ follicular helper T cell infiltration predicts breast cancer survival. J Clin Invest. 2013; 123(7):2873-92. PMC: 3696556. DOI: 10.1172/JCI67428. View

Garufi G, Carbognin L, Schettini F, Segui E, Di Leone A, Franco A . Updated Neoadjuvant Treatment Landscape for Early Triple Negative Breast Cancer: Immunotherapy, Potential Predictive Biomarkers, and Novel Agents. Cancers (Basel). 2022; 14(17). PMC: 9454536. DOI: 10.3390/cancers14174064. View

Li R, Berglund A, Zemp L, Dhillon J, Putney R, Kim Y . The 12-CK Score: Global Measurement of Tertiary Lymphoid Structures. Front Immunol. 2021; 12:694079. PMC: 8276102. DOI: 10.3389/fimmu.2021.694079. View

Song I, Heo S, Bang W, Park H, Park I, Kim Y . Predictive Value of Tertiary Lymphoid Structures Assessed by High Endothelial Venule Counts in the Neoadjuvant Setting of Triple-Negative Breast Cancer. Cancer Res Treat. 2016; 49(2):399-407. PMC: 5398384. DOI: 10.4143/crt.2016.215. View

Schumacher T, Thommen D . Tertiary lymphoid structures in cancer. Science. 2022; 375(6576):eabf9419. DOI: 10.1126/science.abf9419. View

Bertucci F, Finetti P, Simeone I, Hendrickx W, Wang E, Marincola F . The immunologic constant of rejection classification refines the prognostic value of conventional prognostic signatures in breast cancer. Br J Cancer. 2018; 119(11):1383-1391. PMC: 6265245. DOI: 10.1038/s41416-018-0309-1. View

Howard F, Villamar D, He G, Pearson A, Nanda R . The emerging role of immune checkpoint inhibitors for the treatment of breast cancer. Expert Opin Investig Drugs. 2021; 31(6):531-548. PMC: 8995399. DOI: 10.1080/13543784.2022.1986002. View

10.

Wolf D, Yau C, Wulfkuhle J, Brown-Swigart L, Gallagher R, Lee P . Redefining breast cancer subtypes to guide treatment prioritization and maximize response: Predictive biomarkers across 10 cancer therapies. Cancer Cell. 2022; 40(6):609-623.e6. PMC: 9426306. DOI: 10.1016/j.ccell.2022.05.005. View